TORONTO — October 27, 2025 Leads & Copy — Medicenna Therapeutics Corp. (TSX:MDNA, Nasdaq:MDNA) announced an expansion of its Superkine IL-2 platform to include new targets in pancreatic and colorectal cancers, boosting shares 8.6 percent this week.
Medicenna Therapeutics’ Superkine IL-2 platform is a next-generation immunotherapy technology designed to enhance and fine-tune the immune system’s response to cancer and other diseases. It’s based on engineered versions of interleukin-2 (IL-2)
The Toronto-based immunotherapy firm said preclinical data supports enhanced tumor infiltration and immune activation, with IND filings planned for 2026. The company also reported continued progress in its Phase 1/2 trial of MDNA11 for solid tumors.
CEO Fahar Merchant said Medicenna is in active discussions with oncology-focused funds and strategic partners to support clinical development and manufacturing scale-up.
Shares are up 24 percent this quarter.
